<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01475929</url>
  </required_header>
  <id_info>
    <org_study_id>IBS2</org_study_id>
    <nct_id>NCT01475929</nct_id>
  </id_info>
  <brief_title>Effect of Probiotic Supplement on Bowel Function</brief_title>
  <acronym>IBS2</acronym>
  <official_title>Effect of Probiotic Supplement on Bowel Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Danisco</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Danisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to analyse the effect of probiotic supplement on symptoms of
      irritable bowel syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the intervention is to analyse the effect of a probiotic supplement in a
      dose-responsive set up on symptoms of irritable bowel syndrome (IBS). Fulfillment of Rome III
      criteria will be used as inclusion criterion. Subjective assessment of bowel symptoms,
      IBS-related quality of life and adequate relief will be assessed as outcome measures.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Protocol violations
  </why_stopped>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in functional bowel symptoms</measure>
    <time_frame>0 weeks, 6 weeks, 12 weeks</time_frame>
    <description>Validated questionnaire</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life</measure>
    <time_frame>0 weeks, 6 weeks, 12 weeks</time_frame>
    <description>Validated questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adequate relief</measure>
    <time_frame>Weekly over 3 month intervention</time_frame>
    <description>Weekly question</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in faecal microbiota</measure>
    <time_frame>0 weeks, 6 weeks, 12 weeks</time_frame>
    <description>Quantification of selected microbes and the intervention strain from faecal samples</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">149</enrollment>
  <condition>Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>Probiotic low</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lower dose of probiotic supplement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Probiotic high</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Higher dose of probiotic supplement</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probiotic supplement</intervention_name>
    <description>A single strain probiotic supplement given at two doses</description>
    <arm_group_label>Probiotic low</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Probiotic high</arm_group_label>
    <other_name>Lactobacillus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects aged 18 to 65 with functional bowel symptoms and fulfilling Rome III criteria
             for IBS will be recruited. Sufficient general health and orientation for participating
             in the study is required and will be evaluated by the MDs.

        Exclusion Criteria:

          -  Diagnosed or suspected organic gastrointestinal diseases or severely impaired general
             health are exclusion criteria.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arthur Ouwehand, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Danisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anna Lyra, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Danisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lea Veijola, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helsinki Health Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sampo Lahtinen, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Danisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anneli Tarpila, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Danisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Herttoniemi Hospital</name>
      <address>
        <city>Helsinki</city>
        <zip>00800</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 20, 2011</study_first_submitted>
  <study_first_submitted_qc>November 17, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 22, 2011</study_first_posted>
  <last_update_submitted>August 11, 2015</last_update_submitted>
  <last_update_submitted_qc>August 11, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 13, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>irritable bowel syndrome</keyword>
  <keyword>probiotic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

